Please assess the completion status of the following clinical trial:

Trial Title: Safety & Efficacy of Zirconium Silicate Dosed for 28 Days in Hyperkalemia.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Provision of written informed consent.~* Over 18 years of age.~* Two consecutive i-STAT potassium values, measured 60-minutes apart, both ≥5.1 mmol/l and measured within 1 day of the first ZS dose on AP Study Day 1.~* Ability to have repeated blood draws or effective venous catheterization.~* Women of childbearing potential must be using two forms of medically acceptable contraception (at least one barrier method) and have a negative pregnancy test at AP Study Day 1. Women who are surgically sterile or those who are post-menopausal for at least 2 years are not considered to be of childbearing potential.~Exclusion Criteria:~* Pseudohyperkalemia signs and symptoms, such as excessive fist clenching hemolyzed blood specimen, history of severe leukocytosis or thrombocytosis.~* Subjects treated with lactulose, Xifaxan or other non-absorbed antibiotics for hyperammonemia within 7 days prior to the first dose of study drug.~* Subjects treated with resins (such as sevelamer acetate or sodium polystyrene sulfonate \[SPS; e.g. Kayexalate®\]), calcium acetate, calcium carbonate, or lanthanum carbonate, within 7 days prior to the first dose of study drug.~* Subjects with a life expectancy of less than 3 months.~* Subjects who are severely physically or mentally incapacitated and who in the opinion of investigator are unable to perform the subjects' tasks associated with the protocol.~* Women who are pregnant, lactating, or planning to become pregnant.~* Subjects with diabetic ketoacidosis.~* Presence of any condition which, in the opinion of the investigator, places the subject at undue risk or potentially jeopardizes the quality of the data to be generated.~* Known hypersensitivity or previous anaphylaxis to ZS or to components thereof.~* Randomization into the previous ZS-002 or ZS-003 studies.~* Treatment with a drug or device within the last 30 days that has not received regulatory approval at the time of study entry.~* Subjects with cardiac arrhythmias that require immediate treatment.~* Subjects on dialysis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sodium zirconium cyclosilicate 10 g three times daily (Type: EXPERIMENTAL): Sodium zirconium cyclosilicate 10 g three times daily for 48 hours (acute phase)
- Placebo once daily (Type: PLACEBO_COMPARATOR): Randomized to mimic doses of experimental drug administered once daily with breakfast for 28 days.
- Sodium zirconium cyclosilicate 5 g once daily (Type: EXPERIMENTAL): Sodium zirconium cyclosilicate (ZS) 5 g once daily for 28 days (maintenance phase)
- Sodium zirconium cyclosilicate 10 g once daily (Type: EXPERIMENTAL): Sodium zirconium cyclosilicate (ZS) 10 g once daily for 28 days (maintenance phase)
- Sodium zirconium cyclosilicate 15 g once daily (Type: EXPERIMENTAL): Sodium zirconium cyclosilicate (ZS) 15 g once daily for 28 days (maintenance phase)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete